Nature of the Business and Basis of Presentation - Additional Information (Details)					6 Months Ended	12 Months Ended
		Dec. 13, 2025 USD ($) $ / shares shares	Oct. 06, 2025 USD ($) $ / shares shares	Apr. 28, 2025 USD ($) $ / shares shares	Dec. 31, 2024 USD ($) $ / shares shares	Dec. 31, 2025 USD ($) $ / shares shares	Apr. 30, 2025 shares
Sale of Stock
Common stock, shares issued | shares					3,672,794	49,316,287
Common Stock Value Per Share | $ / shares				$ 0.0001	$ 0.0001	$ 0.0001
Proceeds from issuance of convertible notes payable	[1]				$ 95,000,000
Net loss					(46,979,000)	$ (127,410,000)
Net cash used in operating activities					(22,614,000)	(94,689,000)
Cash and cash equivalents, and investments						336,200,000
Cash and cash equivalents					69,386,000	88,438,000
Investments					$ 0	$ 247,720,000
Aerovate Therapeutics, Inc.
Sale of Stock
Reverse stock split				1-for-35
Convertible Notes
Sale of Stock
Proceeds from issuance of convertible notes payable				$ 95,000,000
Accrued interest				$ 8,300,000
Pre-Merger Jade Common Stock
Sale of Stock
Common stock, shares issued | shares				43,947,116
Common stock warrants exercisable | shares				12,305,898
Common Stock Value Per Share | $ / shares				$ 5.9407
Preferred stock convertible ratio				0.6311
Pre-Funded Warrants
Sale of Stock
Number of pre-funded warrants exercised for common stock | shares				12,305,898
Warrant exercise price per share | $ / shares				$ 5.9406
Aggregate amount of pre funded warrant				$ 334,200,000
Number of common shares issued | shares			1,402,092
Price per share | $ / shares			$ 9.1399
Net proceeds from private placement			$ 126,400,000
Net of issuance costs			$ 8,600,000
Pre-Funded Warrants | Aerovate Therapeutics, Inc.
Sale of Stock
Number of pre-funded warrants exercised for common stock | shares				7,766,247
Common Stock | Aerovate Therapeutics, Inc.
Sale of Stock
Common stock, shares issued | shares				27,734,940
Common Stock | Private Placement
Sale of Stock
Number of common shares issued | shares		3,214,286	13,368,164
Price per share | $ / shares		$ 14	$ 9.14
Net proceeds from private placement		$ 43,900,000
Net of issuance costs		$ 1,100,000
Series Seed Convertible Preferred Stock
Sale of Stock
Preferred stock, par value | $ / shares				$ 0.0001
Convertible shares | shares							12,622
Series A Preferred Stock
Sale of Stock
Common Stock Value Per Share | $ / shares				$ 0.0001
Convertible shares | shares				1,000
Preferred stock convertible ratio				0.0006311		1
Shares to be issued in denominator for calculation | shares				1,000

[1] Includes no related party amount for the year ended December 31, 2025 and $20.0 million for the period from June 18, 2024 (inception) to December 31, 2024.